• Does Pioglitazone Have the Same Effects on NASH in Patients With vs Without Diabetes?

Does Pioglitazone Have the Same Effects on NASH in Patients With vs Without Diabetes?

Patients with prediabetes and nonalcoholic steatohepatitis (NASH) benefit nearly as much from pioglitazone therapy as those with type-2 diabetes, researchers report in the April issue of Clinical Gastroenterology and Hepatology. The diabetes drug reduced fibrosis in non-diabetic patients with NASH, the clinical study found, although to a lesser extent than in patients

Read more

Podcast: How Does Fatty Liver Affect Risk for Cardiovascular Disease?

Modification of risk factors for cardiovascular disease—particularly dyslipidemia—is required to reduce morbidity and mortality in patients with nonalcoholic fatty liver disease (NAFLD). In a Perspective article published in the July issue of Clinical Gastroenterology and Hepatology, Kathleen E. Corey and Naga Chalasani discuss the increased risk of cardiovascular disease among patients with NAFLD, and strategies

Read more